Drug Profile
CNTO 3649
Alternative Names: CNTO3649Latest Information Update: 14 Oct 2014
Price :
$50
*
At a glance
- Originator Centocor Ortho Biotech
- Developer Janssen Biotech
- Class Antihyperglycaemics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 14 Oct 2014 No development reported - Phase-I for Type-2 diabetes mellitus in Japan (SC)
- 14 Oct 2014 No development reported - Phase-I for Type-2 diabetes mellitus in USA (IV)
- 14 Oct 2014 No development reported - Phase-I for Type-2 diabetes mellitus in USA (SC)